Users Online: 26
Home
About us
Editorial board
Search
Ahead of print
Current issue
Archives
Submit article
Instructions
Subscribe
Contacts
Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Citation statistics : Table of Contents
2015| October-December | Volume 4 | Issue 4
Online since
February 8, 2016
Archives
Previous Issue
Next Issue
Most popular articles
Most cited articles
Show all abstracts
Show selected abstracts
Export selected to
Cited
Viewed
PDF
NEURO ONCOLOGY: REVIEW ARTICLE
Recurrent Glioblastoma: Where we stand
Sanjoy Roy, Debarshi Lahiri, Tapas Maji, Jaydip Biswas
October-December 2015, 4(4):163-173
DOI
:10.4103/2278-330X.175953
PMID
:26981507
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
11
2,388
603
HEAD AND NECK CANCER: REVIEW ARTICLE
A relationship between quality-of-life and head and neck cancer: A systemic review
Sujal Mitul Parkar, Mihir N Shah
October-December 2015, 4(4):179-182
DOI
:10.4103/2278-330X.175955
PMID
:26981509
Aim:
The aim was to identify the literature and to assess the association between quality-of-life (QoL) and head and neck cancer (HNC) related outcomes systemically.
Materials and Methods:
The full articles published in English language bio-medical journals between 1992 and December 2014 were searched using Medline database. The keywords used for searching the articles include the combination of "health-related of QoL," "QoL," "HNC." The search limited only to the observational studies using questionnaires European Organization for Research and Treatment of Cancer (EORTC) QLQ C 30 and EORTC QLQ H and N 35. Purely psychological studies were excluded.
Results:
A total of 5055 articles were retrieved, and 16 articles were selected for this review. Of 16 observational studies, 13 (81.25%) were prospective cohort studies while remaining 3 (18.75%) were cross-sectional studies. The main findings of the studies revealed that the treatment of HNC had a statistically significant influence on QoL. Others associated factors like age, female sex, duration of treatment, advance tumor, and site of the tumor has also the impact on QoL on patients suffering from HNC.
Conclusion:
This review provides evidence for a positive relationship between cancer-related outcomes and QoL. Assessment of QoL in relation to HNC with proper methodology and validated instruments is lacking hence there is a need for further evidence to support the relation between cancer and QoL.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
5
634
278
HEAD AND NECK CANCER: ORIGINAL ARTICLE
To evaluate disparity between clinical and pathological tumor-node-metastasis staging in oral cavity squamous cell carcinoma patients and its impact on overall survival: An institutional study
Karan Gupta, Naresh K Panda, Jaimanti Bakshi, Ashim Das
October-December 2015, 4(4):183-185
DOI
:10.4103/2278-330X.175957
PMID
:26981511
Background:
Accurate clinical staging is important for patient counseling, treatment planning, prognostication, and rational design of clinical trials. In head and neck squamous cell carcinoma, discrepancy between clinical and pathological staging has been reported.
Objective:
To evaluate any disparity between clinical and pathological tumor-node-metastasis (TNM) staging in oral cavity squamous cell carcinoma (OCSCC) patients and any impact of the same on survival.
Materials
and
Methods:
Retrospective chart review from year 2007 to 2013, at a tertiary care center.
Statistical
Analysis:
All survival analyses were performed using SPSS for Windows version 15 (Chicago, IL, USA). Disease-free survival curves were generated using Kaplan-Meier algorithm.
Results:
One hundred and twenty-seven patients with OCSCC were analyzed. Seventy-nine (62.2%) were males and 48 (37.8%) females with a mean age at presentation 43.6 years (29-79 years). The highest congruence between clinical and pathological T-staging seen for clinical stage T1 and T4 at 76.9% and 73.4% with pathological T-stage. Similarly, the highest congruence between clinical and pathological N-stage seen for clinical N0 and N3 at 86.4% and 91.7% with pathological N-stage. Of clinically early stage patients, 67.5% remained early stage, and 32.5% were upstaged to advanced stage following pathological analysis. Of the clinically advanced stage patients, 75% remained advanced, and 25% were pathologically downstaged. This staging discrepancy did not significantly alter the survival.
Conclusion:
Some disparity exists in clinical and pathological TNM staging of OCSCC, which could affect treatment planning and survival of patients. Hence, more unified and even system of staging for the disease is required for proper decision-making.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
2
343
130
LETTERS TO THE EDITOR
Late effects of cancer treatment in breast cancer survivors
Hanne Verbelen, Nick Gebruers, Wiebren Tjalma
October-December 2015, 4(4):182-182
DOI
:10.4103/2278-330X.175956
PMID
:26981510
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
2
351
117
NEURO ONCOLOGY: ORIGINAL ARTICLE
Outcomes of adult medulloblastoma treated with a multimodality approach: A tertiary cancer center experience
Supriya Mallick, Ajeet Kumar Gandhi, Rony Benson, Daya Nand Sharma, Kunhi Parambath Haresh, Subhash Gupta, Pramod Kumar Julka, Goura Kisor Rath
October-December 2015, 4(4):174-178
DOI
:10.4103/2278-330X.175954
PMID
:26981508
Objectives:
Adult medulloblastoma (AMB) is a rare central nervous system tumor. We aimed to analyze the treatment outcomes of AMB treated at our institute with surgery followed by craniospinal irradiation (CSI) and adjuvant chemotherapy.
Methods:
We retrospectively evaluated the treatment charts of 31 patients of AMB treated from 2003-2011. The patient demography, treatment details and survival data were collected in a predesigned proforma. Kaplan Meier method was used to analyze disease free survival (DFS) and the impact of prognostic factors was determined by univariate analysis (log rank test).
Results:
Male: Female ratio was 21:10. Cerebrospinal fluid dissemination was noted in 16% cases. CSI (36 Gray at 1.8 Gray/fraction to entire neuraxis and 20 Gray at 2 Gray/fraction boost to posterior fossa) was used in all cases. 26 patients received adjuvant chemotherapy (carboplatin plus etoposide). Median follows up was 26.85 months (9.47-119.73 months). The estimated 3 and 5 years DFS was found to be 84.9% and 50.7% respectively. On univariate analysis, tumor located laterally had a trend towards better DFS (HR 3.04; 95%CI 0.722 to 12.812;
P
= 0.07) compared to midline tumors. Other factors like adjuvant chemotherapy, age, gender, surgical extent had no statistically significant impact on survival.
Conclusion:
The results of our study (largest series from India) show that the regimen of surgery, adjuvant CSI and chemotherapy is feasible and confers descent survival. AMB patients should be treated with a multimodality approach in a tertiary care centre.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
2
532
180
INDEX
Index
October-December 2015, 4(4):0-0
Full text not available
[PDF]
[Mobile Full text]
[EPub]
-
113
65
LETTERS TO THE EDITOR
Palliative low dose fortnightly methotrexate in oral cancer
Sim Sai Tin, Viroj Wiwanitkit
October-December 2015, 4(4):188-188
DOI
:10.4103/2278-330X.175959
PMID
:26981513
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
214
65
Radiobiological case study of volumetric modulated arc therapy planning techniques for treatment of low-risk prostate cancer in patients with bilateral hip prostheses
S Rana, S Pokharel
October-December 2015, 4(4):159-178
DOI
:10.4103/2278-330X.175951
PMID
:26981505
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
343
116
MOLECULAR ONCOLOGY: ORIGINAL ARTICLES
Correlation between cyclin D1 expression and standard clinicopathological variables in invasive breast cancer in Eastern India
Santanu Sarkar, Aditya Kanoi, Jayanta Bain, Rajarshi Gayen, Kashi Nath Das
October-December 2015, 4(4):155-159
DOI
:10.4103/2278-330X.175950
PMID
:26981504
Introduction:
Breast cancer is the leading oncogenic threat in South-East Asian women showing an inexplicable biological aggressiveness. High expression of cyclin D1, a key molecule in breast cancer pathogenesis, has been shown by previous studies in the Western world to be associated with favorable tumoral characteristics. Apart from determining the correlation between cyclin D1 expression and standard clinicopathological variables in invasive breast cancer in Eastern India, questions that we aimed to answer through this study included: Is there a significant regional difference in expression patterns of this protein? And if yes, can it possibly account for the epidemiological differences in breast cancer occurrence and biological behavior? Finally, is testing for overexpression of this protein in regions with limited resources beneficial?
Materials and
Methods:
The present study was carried out on 110 previously untreated, female patients with primary breast carcinoma. Cyclin D1 expression was determined by immunohistochemistry using specific anti-cyclin D1 monoclonal antibodies.
Results:
Overexpression of cyclin Dl was found in 78 of 110 cases (70.9%). High expression of cyclin D1 showed a significant negative correlation with tumor size (
P
= 0.023) and tumor grade (
P
= 0.045). Estrogen receptor and progesterone receptor positive cases showed a significantly positive correlation with cyclin D1 overexpression (
P
= 0.026 and 0.046, respectively). Interestingly, cyclin D1 positivity showed a strong correlation with the type of surgical procedure performed (
P
= 0.002).
Conclusion:
Cyclin D1 overexpression in breast cancer is associated with less aggressive tumoral characteristics. Furthermore, its potential epidemiological role and utility as a prognostic marker have been discussed.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
470
161
Molecular classification and prognostication of 300 node-negative breast cancer cases: A tertiary care experience
KM Zuhara Shemin, NV Smitha, Annie Jojo, DK Vijaykumar
October-December 2015, 4(4):160-162
DOI
:10.4103/2278-330X.175952
PMID
:26981506
Background:
The proportion of node-negative breast cancer patients has been increasing with improvement of diagnostic modalities and early detection. However, there is a 20-30% recurrence in node-negative breast cancers. Determining who should receive adjuvant therapy is challenging, as the majority are cured by surgery alone. Hence, it requires further stratification using additional prognostic and predictive factors.
Subjects and
Methods:
Ours is a single institution retrospective study, on 300 node-negative breast cancer cases, who underwent primary surgery over a period of 7 years (2005-2011). We excluded all cases who took NACT. Prognostic factors of age, size, lymphovascular emboli, estrogen receptor (ER), progesterone receptor (PR), HER2neu Ki-67, grade and molecular classification were analyzed with respect to those with and without early events (recurrence, metastases or second malignancy, death) using-Pearson Chi-square method and logistic regression method for statistical analysis.
Results:
Majority belonged to the age group of 50-70 years. On univariate analysis, size >5 cm (
P
= 0.03) and ER negativity had significant association (
P
= 0.05) for early failures; PR negativity and lymphovascular emboli (LVE) had borderline significance (
P
= 0.07). Multivariate analysis showed size >5 cm to be significant (
P
= 0.04) and LVE positivity showed borderline significant association (
P
= 0.07) with early failures. About 62% belonged to luminal category followed by basal-like (25%) in molecular classification.
Conclusions:
ER negativity, PR negativity, LVE/lymphovascular invasion positivity and size >5 cm (T3 and T4) are associated with poor prognosis in node-negative breast cancers.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
433
136
MYELODYSPLASTIC SYNDROME: REVIEW ARTICLE
Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes
Sachi Jain Taran, Rakesh Taran
October-December 2015, 4(4):186-188
DOI
:10.4103/2278-330X.175958
PMID
:26981512
This review article highlights the current role of iron chelation in MDS to optimize survival and quality of life. Its role in specific subtypes of MDS is also discussed.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
-
484
171
Feedback
Subscribe
Sitemap
|
What's New
|
Feedback
|
Disclaimer
© South Asian Journal of Cancer | Published by Wolters Kluwer -
Medknow
Online since 10 May, 2012